Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Bausch Health Companies Inc (BHCN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
174.30 +0.00    +0.00%
01/04 - Closed. Currency in MXN ( Disclaimer )
  • Volume: 0
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 174.30 - 174.30
Type:  Equity
Market:  Mexico
ISIN:  CA0717341071 
Bausch Health 174.30 +0.00 +0.00%

Bausch Health Companies Inc Company Profile

 
Get an in-depth profile of Bausch Health Companies Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

20270

Equity Type

ORD

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Contact Information

Address 2150 St. ElzEar Boulevard West
Laval, H7L 4A8
Canada
Phone 514 744 6792
Fax -

Top Executives

Name Age Since Title
John A. Paulson - 2022 Chairman of the Board
H. Christian Fibiger 80 2008 Chairman of External Advisory Board
Robert N. Power 66 2008 Independent Director
Thomas J. Appio 61 2016 CEO & Director
Russel C. Robertson 75 2016 Independent Director
John Alfred Paulson 68 2022 Independent Chairman
Richard C. Mulligan 68 2022 Independent Director
Robert H. Lenox - 2009 Member of the External Advisory Board
Karoly Nikolich 76 2009 Member of the External Advisory Board
Kathleen Clarence-Smith 77 2009 Member of the External Advisory Board
Amy B. Wechsler 54 2016 Independent Director
Thomas Warren Ross 73 2016 Lead Independent Director
Sarah B. Kavanagh 67 2016 Independent Director
Brett M. Icahn 45 2021 Independent Director
Steven D. Miller 35 2021 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

BHC Comments

Write your thoughts about Bausch Health Companies Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Mohammad Ali
Mohammad Ali Mar 27, 2024 14:41
Saved. See Saved Items.
This comment has already been saved in your Saved Items
depends on quarterly results
David Harrison
David Harrison Mar 02, 2021 15:51
Saved. See Saved Items.
This comment has already been saved in your Saved Items
bullish
Cody Tilma
Cody Tilma Feb 26, 2020 14:33
Saved. See Saved Items.
This comment has already been saved in your Saved Items
will look at this again at around $25, bearish till then
Peter Petrossi
Peter Petrossi Feb 19, 2020 11:48
Saved. See Saved Items.
This comment has already been saved in your Saved Items
sorry...who wrote the next comment.
Peter Petrossi
Peter Petrossi Jul 11, 2019 13:10
Saved. See Saved Items.
This comment has already been saved in your Saved Items
sing it! dreaming..... only dreaming. at what point do analyst get banned for 'fake' analysis?
Srinath Gunaratne
Srinath Gunaratne Aug 14, 2016 0:30
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I do not trust analyst target. Last earnings did not meet analyst expectations. May be long term will reach target 90.00. I bought at 29.00 and sold at 35.00. I follow the chart and will buy again below 30.00.
Mohammed Ali
Mohammed Ali Jul 07, 2016 23:37
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Analyst target for VRX is $90 I am in with 50 shares at $36 hoping analyst to be right this time about $90 target So should I be long on this stock ? Please share your comments
Jeremiah Cox
Jeremiah Cox Jul 07, 2016 23:37
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Stay AWAY!!!!! Dangerous. Clinton will hit on Pharma constraints tonight. With 36 you will be ok in the long run, 6% as of now and have a feeling that 4% more is on the way
PAKAWA pakawa
PAKAWA pakawa Jul 07, 2016 23:37
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Jeremiah Cox  . re: "have a feeling", never be emotional about the markets.......it'd hurt you
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email